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Abstract
Chronic diseases such as cancer, diabetes, heart diseases, chronic kidney disease (CKD) require a drug management
system that ensures a stable and robust output of the patient’s condition in response to drug dosage. In the case of
CKD, the patients suffer from the deficiency of red blood cell count and external human recombinant erythropoietin
(EPO) is required to maintain healthy levels of hemoglobin (Hb). Anemia is a common comorbidity in patients with
CKD. For an efficient and robust anemia management system for CKD patients instead of traditional population-based
approaches, individualized patient-specific approaches are needed. Hence, individualized system (patient) models for
patient-specific drug-dose responses are required. In this research, system identification for CKD is performed for
individual patients. For control-oriented system identification, two robust identification techniques are applied: (1)
l1 robust identification considering zero initial conditions and (2) semi-blind robust system identification considering
non-zero initial conditions. The EPO data of patients are used as the input and Hb data is used as the output of the
system. For this study, individualized patient models are developed by using patient-specific data. The ARX one-step-
ahead prediction technique is used for model validation at real patient data. The performance of these two techniques
is compared by calculating minimum means square error (MMSE). By comparison, we show that the semi-blind robust
identification technique gives better results as compared to l1 robust identification.
Index terms— l1 robust system identification, Semi-blind robust system identification, Robust system identification,
Anemia management, Chronic kidney disease.
1 Introduction
In recent years, the need for drug management in bio-engineering is becoming one of the prominent applications for
control systems researchers. For feedback control systems, the mathematical model of the plant is important to apply
control and prediction algorithms. As the system model for the individual patient is different and complex to write its
mathematical form. In chronic kidney disease (CKD), the human body is not able to produce enough erythropoietin,
a glycoprotein that produces red blood cells [1]. The patients of this disease are treated with the recombinant human
erythropoietin (EPO). The dosage of EPO to the human body increases the hemoglobin (Hb) levels [2]. According to the
National Kidney Foundation’s Dialysis, the Hb level should be in the range of 11 and 12 g/dL in the response of EPO
dosage [3].
Presently, the medical centers have developed their own EPO management systems based on the average (population-
based) response medication. While population models may be useful in the analysis of drug properties at large, they
are not well suited to guide treatment of individual patients. In order to effectively address the impact of inter- and
intra-individual variability in dose-response characteristics, personalized, patient-specific models are needed. Therefore,
medical institutes are in need of a stable and robust system for individualized anemia management. The key point
in designing an efficient individualized anemia management system is to find accurate patient-specific dose-response
models.
Many researchers have attempted to develop patient models for anemia management. Bayesian-based drug delivery
using population patient data is discussed in [4]. Artificial Intelligence-based neural network models are discussed
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in [5] [6] [7]. Some researchers attempted to identify individual patient models in [8]. In [9] the main focus was to
predict the value for EPO instead of Hb, which is not desired as predicting Hb level gives values of EPO but not true for
vise versa. However,
most of these models are based on predetermined model structure and noise distribution, which is not suitable for
anemia management as each patient poses different model characteristics. The models obtained by the classical system
identification techniques do not yield good results as it assumes that predefined model structure and model order are close
to the actual system and one mathematical model works for all dynamics regardless of complexity and disturbances in
the system. The modeling stage should include the effect of all disturbances and uncertainties which are being introduced
during operations. In contrast to classical identification techniques, robust system identification takes into account system
uncertainties, unmodeled dynamics and model complexity, i.e., there is no assumption on the model order, uncertainties
and noise affecting data.
For robust control, the design requires the nominal model and uncertainty bound on this model [10]. Therefore,
robust system identification techniques should provide a nominal model and uncertainty bound on it [11]. The robust
system identification procedure does not require large measurement data set or information of measurement noise nor the
information on the structure of the system to be identified is required. In this technique, the information on the maximum
gain of the system K, the stability margin of the system response ρ, and a bound on the noise is required. Depending on
the nature of the a posteriori information, the robust identification techniques may lead to different identification methods.
The selection of robust system identification method depends on the data type as time-domain data and frequency domain
data pose different characteristics and different techniques are applied to obtain a model for the data type [12]. For
frequency domain data, the H∞-identification technique is implemented, which calculates the uncertainty bounds in
terms of the H∞-norm. For time-domain data, the l1-identification technique is implemented, which calculates an l1-
error bound. However, sometimes both time and frequency domain data may be available for a single plant. In this case,
the mixed H∞/l1 robust identification procedure is used [13].
In this research work, the individual patient model for anemia management is obtained using robust system identifi-
cation techniques and patient-specific data. For system identification, the l1 robust system identification and Semi-Blind
system identification techniques [14] are used. The system model is a combination of a nominal model and uncertainty
bound. Both of these identification techniques, develop a nominal model and uncertainty bound using patient-specific
dose-response (EPO-Hb) data.
We summarize our contributions as follows:
1. We present an individualized patient model for anemia patients using l1 robust system identification assuming zero
initial conditions. The system model is reduced to 4th order which is suitable for control synthesis techniques.
2. We present an individualized patient model for anemia patient using semi-blind robust system identification by
incorporating the effects of initial conditions instead of assuming it zero.
3. Validation of models obtained by l1 robust system identification and semi-blind system identification using ARX
one-step-ahead prediction [15].
4. Comparison and error analysis of the obtained models for prediction are also provided using minimum mean
squared error (MMSE) analysis.
The remainder of this paper is organized as follows. First, we discuss the l1 robust system identification in Section 3.
Then, we introduce the semi-blind robust system identification in Section 4. Finally, we present the system models results
obtained by the one-step ahead prediction along with the error analysis for both techniques in Section 5 followed by the
conclusion.
2 System Identification
The plant model is the set of mathematical equations that describes the system behavior in response to the system
input. The typical feedback control system is shown in Fig. 1.
Figure 1: Feedback control system of a plant.
The purpose of system identification is to develop a low order model of the plant by using finite, noisy sensor data,
which can be controllable and observable by implementing suitable controller and observer respectively. In this work,
the system model is the combination of a parametric and non-parametric portion given as:
G = Gp +Gnp (1)
The non-parametric portion Gnp describes the internal behavior of the plant. This portion requires less prior knowledge
of the system such as a model for internal behavior of physiological systems. On the other hand, the parametric portion
Gp describes the input to output relation. For the parametric portion, the prior knowledge is important, which urges
the need for initial condition effect. The robust system identification techniques are good for non-parametric portions
such as l1 robust identification. To incorporate the effect of initial conditions, the semi-blind identification technique is
introduced, which uses the same framework as l1 robust identification but also computes the parametric portion.
Next, we formally define the problem.
Problem 1 Considering equation 2, obtain the plant model G which gives output yk as Hb level in response to input uk
of EPO dosage to patients of CKD.
yi = Gui + ηi, (2)
|ηi| ≤ i, (3)
where i is the maximum bound on noise, which is unknown but bounded.
3 l1 Robust Identification
The l1 robust identification, is the method to obtain a system model with a minimum prior knowledge about the
system [16]. The classical identification techniques assume that the model has a fixed order and structure and probabilistic
noise distribution. However, l1 robust identification does not assume a fixed order model or noise distribution [17]. It
requires minimal prior information, such as the maximum gain on the system K > 0, the lower bound on the relative
stability margin of the system dynamics ρ > 1, and an upper bound on the noise in measurements  > 0. The model
obtained by this technique provides the bound on modeling error which shows the robustness of this method as shown in
the following equation.
G(z) = Go(z) + ζ, (4)
‖G(z)−Go(z)‖∞ 6 ζ, (5)
where Go(z) is the nominal model and ζ is the mismatch between the nominal model and plant model which is the effect
of model error and measurement error. The equation 5 provides the maximum bound on the modeling error. This bound
is hardbound whereas the classical methods provide soft bounds based on probabilistic assumptions. By this method,
consider a linear time-invariant (LTI) operator g of system class S, which maps u from input space to y in output space.
The impulse response of g is given as follows:
G(z) =
∞∑
i=0
giz
−i, (6)
where
gi = Kρi, (7)
where K is the bound on impulse response and ρ is the decay rate. By the discussion, for N samples of data, the robust
identification problem can be defined as follows:
Problem 2 Given the a priori and the a posteriori information, determine:
• whether the priori and posteriori information are consistent, i.e decide whether the models in G∞,ρ interpolates
the given measurement points with error bounded by the priori error information. The priori and posteriori
information is consistent if and only if, Γ is a non-empty set.
Γ
.
= g ∈ S|yi = (g ∗ ui) + ηi (8)
• If the two sources of information are consistent, then obtain such a model as well as a bound on the worst-case
identification error.
The consistency is determined by using Caratheˆodory-Feje´r Interpolation [18], defined below:
Problem 3 Given sequence of complex points, gi, i = 0, 1, 2 · · ·N − 1, determine a function G(z) such that
G(z) = g0 + g1z
1 + g2z
2 + · · ·+ gN−1zN−1 + gˆNzN (9)
The solution of this problem consists on following inequality.
I − T ∗g Tg ≥ 0, (10)
where Tg it the nxn lower triangular Toeplitz matrix of sequence {g0, g1, · · · gn−1}. The solution of Caratheˆodory-Feje´r
Interpolation exits only if vector g = g0 + g1z1 + g2z2 + · · · + gN−1zN−1 exists such that following Linear Matrix
Inequality (LMI) holds:
M(g) =
[
KR−2 (TNg )T
(TNg ) KR
−2
]
≥ 0,∣∣y − TNu g∣∣ ≤ ,
where R is the diagonal matrix with coefficients
{
1, ρ, ρ2, ρ3 · · · ρN−1}. The TNu and TNg are the nxn upper triangle
matrix with coefficients {uo, u1, u2, · · ·uN−1} and {go, g1, g2, · · · gN−1}, respectively.
For non-parametric identification, the technique gives hard conservative results. To get less conservative results, the
information on the parametric portion can also be included as priori information. Assuming the non-parametric portion
belongs to τ , defined as:
τ
.
= P (z) = pTGp(z), p ∈ <Np (11)
where p ∈ <Np is unknown vector of some prior known component Gp and Np is the number of unknown parameters to
be determined. This does not change the LMI problem defined above. It only changes the error bound defined as below:∣∣y − TNu pP + TNu g∣∣ ≤ ,
The G(z) can be obtained by following set of equations [19]:
G(z) = CG(zI −AG)−1BG +DG
AG = A− [CT−C− + (AT − I)MR]−1CT−C−(A− I)
BG = −[(AT − I)MR + CT−C−]−1C−
CG = C+[(A
T − I)MR + CT−C−]−1CT−C−(A− I)− C+(A− I)
DG = C+[(A
T − I)MR + CT−C−]−1CT−
A =
[
0 INxN
0 0
]
C=
N︷ ︸︸ ︷[
1 0 · · · 0]
C+ = g
TR/K
In l1 robust identification, the initial conditions are considered as zero, which is suitable for non-parametric estimation.
However, to be able to include the effect of initial conditions in the system model the semi-blind robust identification
technique is introduced in the Section- 4.
4 Semi-Blind System Identification
The response of dynamic systems is highly affected by its state at t = 0. To include the initial condition effects,
the identification technique described in Section 3 needs to be improved. The semi-blind robust identification technique
takes into account information about the initial conditions of the system [20]. The problem for semi-blind identification
can be defined as follows:
Problem 4 Given input sequence u, output sequence y, noise bound ∈ N , maximum stability gain and characteristics
of past input u−, determine G(z) = Gp(z) + Gnp(z) which is compatible with priori and posteriori information, such
that τ is non-empty set.
τ(y)
.
= yi =
N∑
i=0
giuN−i + CgAN−1g (Γ
N
g u
−)i=0 (12)
where g0 = Dg; gi = Cg(Ag)i−1Bg
The solution to the above equation (12) involves solving a Bi-Affine Matrix, which is a non-convex, NP-hard problem.
The above problem can be converted to the convex problem as mentioned in [20], which preserves the controllability and
observability of the system. The convex problem can be defined as follows:
Problem 5 Determine G(z) = Gp(z) + Gnp(z), which is compatible with a priori and a posteriori information, such
that τ is non-empty set:
τ(y) =
{
G(z) ∈ S : yi − (TNg u)i + (ΓNg u−)i
}
(13)
where,
∣∣(ΓNg u−)i∣∣ 6 γKu; i = 0, 1, · · · , N − 1 and TNg is the Toeplitz matrix and ΓNg is the Hankel matrix.
The first part of the τ set corresponds to the system response for input u and the later part provides information for
system response for past inputs u−. This problem can be solved by following LMIs [20][21].
M(g) =
[
KR−2 (TNg )T
(TNg ) KR
−2
]
≥ 0,
∣∣y − (TNu pP + TNu g)− ΓNg u−∣∣ ∈ N,
−γKu 6 ΓNg u− 6 γKu
where γ,Ku, p, P represent system gain, a bound Ku on the norm of sequence u−, affine parameters and the parametric
portion of the system.
The Fig. 2 shows the framework for semi-blind identification. As the response to the EPO dosage as measurement of
Hb is also effected by the past inputs u−, the parametric part should be an integrator to accommodate all the effects of
the inputs before t = 0, i.e initial conditions.
Figure 2: Framework for semi-blind identification.
As we have discussed the tools for parametric/non-parametric robust system identification to obtain a system model
for the patients of chronic kidney disease for anemia management to control Hb level in response to EPO dosage. The
Section- 5 shows the implementation of l1 robust identification and semi-blind robust identification on real patient data
along with system validation using ARX one-step-ahead prediction method.
5 Simulation Results for Model Identification
To obtained a model using identification techniques discussed in the above section, the EPO medication data and Hb
measurement data of fifty patients have been obtained from the University of Louisville, Kidney Disease program. The
EPO dosage is administrated three times a week and the Hb level is tested for only once a week. For system identification,
the input/output data should be of the same length, hence three dosages of EPO per week are averaged which corresponds
to a single Hb measurement. For model validation, the autoregressive model with exogenous output (ARX) is used [22],
the difference equation for the ARX model is given as follows:
a0y(k) + a1y(k − 1) + a2y(k − 2) + · · ·+ any(k − n) = b1u(k − n) + · · ·+ bnu(k − 1) (14)
The models obtained by the l1 robust identification and the semi-blind robust identification technique are compared by
calculating minimum mean squared error (MMSE). The normalized MMSE mathematical definition in given in equa-
tion (15)
MMSE(k) =
1
N
N∑
i=0
‖y(k)− yˆ(k)‖2
y(k)
(15)
To obtain a robust model, the parameters ρ = 1.01, η = 0.31 and N = 20 are used as priori information for all
patients.
We present here the results for four patients, patient-1, patient-11, patient-21 and patient-32. The system model for
patient number 1 obtained by l1 robust identification and the ARX one step ahead prediction is shown below:
G1(z) =
59.3z4 − 179.6z3 + 248.6z2 − 211z + 92.98
z4 − 2.256z3 + 2.638z2 − 1.904z + 0.6192 (16)
(a) Model validation by ARX one-step ahead prediction for full
and reduced order models along with MMSE analysis.
(b) Weekly EPO dosage and Hb data for Patient 1.
Figure 3: Responses and MMSE analysis of the patient-1 full and reduced order models obtained by the l1 robust
identification.
The 20 samples of measurement of dose-response (EPO-Hb) data are used for the identification. After 20 samples
the output is predicted by the ARX one-step-ahead prediction. As it is seen in Figure 3, the results of the l1-robust
identification algorithm is poor. Even for the data points used in the identification (the first 20 data points) the output of
the reduced order model misses the data points while the full order model matches the data points. However, for the data
points (after the first 20 data points) which are not used in the identification both the full as well as reduced order models
predictions do not match with the validation data. As a result, MMSE values as seen in Figure 3(a) are quite large.
Different than the patient-1, patient-11 dose-response data presents a more challenging case due to the several missing
input (EPO) data for weeks 11,13,15,16,18 through 20. As before, the first 20 data points were used in the l1-robust
identification algorithm to find the model. Then the full order model (20th order) is reduced to the 4th order model. The
full and reduced order models for patient-11 and model predictions are shown in Fig. 4.
G11(z) =
136.9z4 − 823.8z3 + 1879z2 − 1908z + 739
z4 − 2.595z3 + 2.555z2 − 1.111z + 0.1788 (17)
(a) Model validation by ARX one-step ahead prediction for full
and reduced order models along with MMSE analysis.
(b) Weekly EPO dosage and Hb data for Patient 11.
Figure 4: Responses and MMSE analysis of the patient-11 full and reduced order models obtained by the l1 robust
identification.
The model for patient number 21 and model validation is shown in Fig. 5. The full and reduced order models for
the patient-21 obtained by the semi-blind robust identification show low in the first 26 weeks of the data set as shown in
MMSE analysis. The responses for full and reduced order models deviate from actual patient data as the EPO dosage is
increased.
G21(z) =
−29.74z4 + 21.66z3 − 11.52z2 + 20.97z − 30.32
z4 − 0.7401z3 + 0.4182z2 − 0.7254z + 0.9384 (18)
(a) Model validation by ARX one-step ahead prediction for full
and reduced order models along with MMSE analysis.
(b) Weekly EPO dosage and Hb data for Patient 21.
Figure 5: Responses and MMSE analysis of the patient-21 full and reduced order models obtained by the l1 robust
identification.
The full order model is of 20th order while the reduced-order model is 4th order for all patients. The model for
patient number 32 and model validation is shown in Fig. 6:
G32(z) =
−584z4 + 2744z3 − 5031z2 + 4262z − 1418
z4 − 3.027z3 + 3.592z2 − 1.968z + 0.4198 (19)
(a) Model validation by ARX one-step ahead prediction for full
and reduced order models along with MMSE analysis.
(b) Weekly EPO dosage and Hb data for Patient 32.
Figure 6: Responses and MMSE analysis of the patient-32 full and reduced order models obtained by the l1 robust
identification.
These models assume the initial conditions equal to zero., which can highly affect the identified model as for the
patients of Chronic Kidney disease (CKD), the past medication effects the state of the patient. Thus, these effects are
included in the model using the semi-blind identification technique. The model of patient 1 obtained by the semi-blind
identification technique and model validation results by ARX one-step-ahead prediction are shown in Fig. 7:
G1(z) =
1.307z4 − 0.9089z3 − 0.2374z2 + 0.9456z + 0.03848
z4 − 1.649z3 + 0.4094z2 + 1.035z − 0.7778 (20)
(a) Model validation by ARX one-step ahead prediction for full
and reduced order models.
(b) MMSE for full order and reduced order models by ARX
one-step ahead prediction
Figure 7: Responses and MMSE analysis of the patient-1 full and reduced order models obtained by the semi-blind
robust identification.
The MMSE analysis for the patient-1 shows less error for the semi-blind robust identification as compared to the l1
robust identification, as the semi-blind robust identification technique accounts the effect of the previous inputs. These
results show that previous medication used by the patient significantly affects the model identification. The system model
for patient number 11 obtained by semi-blind robust identification and model validation is shown in Fig. 8:
G11(z) =
1.302z4 − 1.092z3 − 0.988z2 + 0.9426z + 0.08707
z4 − 1.867z3 + 0.1278z2 + 1.542z − 0.7983 (21)
(a) Model validation by ARX one-step ahead prediction for full
and reduced order models.
(b) MMSE for full order and reduced order models by ARX
one-step ahead prediction.
Figure 8: Responses and MMSE analysis of the patient-11 full and reduced order models obtained by the semi-blind
robust identification.
The system model for patient number 21 obtained by semi-blind robust identification and model validation by the
ARX one-step-ahead prediction is shown in Fig. 9:
G21(z) =
1.417z4 + 1.594z3 + 1.217z2 + 1.157z + 0.117
z4 + 0.1094z3 − 0.2046z2 − 0.07295z − 0.7574 (22)
(a) Model validation by ARX one-step ahead prediction for full
and reduced order models.
(b) MMSE for full order and reduced order model by ARX one-
step ahead prediction.
Figure 9: Responses and MMSE analysis of the patient-21 full and reduced order models obtained by the semi-blind
robust identification.
The 4th order model response for the patient-21 shows higher MMSE analysis for weeks 29 through 40. In this
duration, the EPO dosage has increased suddenly which introduces a disturbance in the system and increases error. The
system model for patient number 32 obtained by semi-blind robust identification and model validation by the ARX
one-steap ahead prediction is shown in Fig. 10:
G32(z) =
2.744z4 + 4.082z3 + 1.548z2 + 0.0005763z + 0.3473
z4 + 0.6091z3 − 0.8802z2 − 0.742z + 0.07692 (23)
(a) Model validation by ARX one-step ahead prediction for full
and reduced order models.
(b) MMSE for full order and reduced order model by ARX one-
step ahead prediction.
Figure 10: Responses and MMSE analysis of the patient-32 full and reduced order models obtained by the semi-blind
robust identification.
The reduced-order model for the patient-32 shows the high error, it is mainly due to the higher values of EPO dosage
as the plot of EPO dosage shows continuous higher values. But the response of the full order model is very close to the
actual patient data, which shows that the increase in a model can further reduce the error for the reduced-order model.
By the MMSE analysis of full order model and reduced-order models obtained by semi-blind identification and l1 robust
identification technique, it is shown that semi-blind provides better results as it includes the effect of the past effect of
medication.
6 Conclusion
In this research work, the individualized system model for patients of chronic kidney disease (CKD) is obtained to
regulate the external human recombinant erythropoietin (EPO) dosage to maintain the hemoglobin (Hb) levels between
11 and 12 g/dL. The l1 robust identification and semi-blind identification technique have been implemented on the data
set of fifty real patients obtained from the University of Louisville, Kidney Disease program. The l1 robust identification
is non-parametric identification which considers the zero initial conditions. However, the semi-blind identification tech-
nique determines the effects of inputs before t = 0 as well as the system model. Both of these techniques do not assume
the probabilistic distribution of noise or predefined model structure. The obtained patient models are validated by using
the ARX one-step prediction method. The minimum mean square error (MMSE) is calculated for each patient between
actual data and predicted data. The error in the model obtained in semi-blind identification techniques is less than l1
robust identification technique. This research work provides a basis to obtain individualized models for new patients.
The next phase is to design the controller for the patient based on the identified models and automate this procedure for
new patients.
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